VIM and breast cancer: In an in vivo investigation using breast cancer orthotopic xenograft tumors, the administration of oleocanthal exhibited the capacity to stabilize E-cadherin while concurrently reducing vimentin expression in recurrent tumors derived from both BT-474 and MDA-MB-231.